Latest Period
Q2 2026
Security Snapshot
Royalty Pharma plc - Class A ordinary shares, par value $0.0001 per share (RPRX) Institutional Ownership
CUSIP: G7709Q104
13F Institutional Holders and Ownership History from Q1 2019 to Q2 2026
Institutions Reporting
638
Shares (Excl. Options)
365,939,259
Price
$56.07
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A ordinary shares, par value $0.0001 per share
- Symbol
- RPRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 365,939,259
- Total 13F value
- $20,502,342,626
- Portfolio coverage rank
- 0.02%
- Share change
- +11,994,082
- Value change
- +$692,560,746
- Number of holders
- 638
- Shares outstanding
- 543,437,496
- SEC-reported price per share
- $58.73
- Insider filing price
- $58.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RPRX - Royalty Pharma plc - Class A ordinary shares, par value $0.0001 per share is tracked under CUSIP G7709Q104.
- 638 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 589 to 638 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $16,994,827,398 to $20,502,342,626.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 638 institutions filings for Q2 2026.
Security key
G7709Q104
Latest holder period
Q2 2026
13F holders
638
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
RPRX full holder history
Royalty Pharma plc SEC filings
Royalty Pharma plc company facts
Royalty Pharma plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G7709Q104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
RPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Legorreta Pablo G. | 19% | -5% | $5,677,614,323 | -$74,017,438 | 101,785,843 | -1.3% | Legorreta G. Pablo | 13 Aug 2026 |
| MORGAN STANLEY | 9.2% | $1,394,427,274 | 38,907,011 | Morgan Stanley | 30 Jun 2025 | |||
| Capital International Investors | 7.7% | +16% | $1,265,287,125 | +$163,578,499 | 32,745,526 | +15% | Capital International Investors | 31 Dec 2025 |
| FMR LLC | 6.5% | -29% | $984,337,180 | -$400,247,331 | 27,900,714 | -29% | FMR LLC | 30 Sep 2025 |
| BlackRock, Inc. | 5.7% | $832,319,492 | 25,445,414 | BlackRock, Inc. | 31 Dec 2024 | |||
| Severgnini Achille G. | 4.8% | -15% | $1,164,070,183 | -$155,603,324 | 21,366,927 | -12% | Severgnini Achille G. | 12 Jun 2026 |
| GENERAL ATLANTIC, L.P. | 3.2% | $510,500,301 | 14,243,870 | General Atlantic, L.P. | 30 Jun 2025 | |||
| VANGUARD GROUP INC | 2.5% | $385,841,061 | 10,936,538 | The Vanguard Group | 30 Sep 2025 |
As of 30 Jun 2026, 638 institutional investors reported holding 365,939,259 shares of Royalty Pharma plc - Class A ordinary shares, par value $0.0001 per share (RPRX). This represents 67% of the company’s total 543,437,496 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
47%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 7.9% | 42,931,597 | -1.5% | 0.13% | $2,407,174,722 |
| Capital International Investors | 6.5% | 35,273,770 | +0.77% | 0.41% | $1,977,800,284 |
| BlackRock, Inc. | 5.1% | 27,832,977 | +7.4% | 0.02% | $1,560,595,060 |
| FMR LLC | 4.5% | 24,513,814 | -2.5% | 0.06% | $1,374,489,542 |
| STATE STREET CORP | 2.3% | 12,338,229 | +12% | 0.02% | $691,804,500 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.1% | 11,193,657 | +479% | 0.06% | $627,629,000 |
| Swedbank AB | 2% | 10,726,608 | -7.4% | 0.52% | $601,440,912 |
| BAILLIE GIFFORD & CO | 1.8% | 10,015,578 | -38% | 0.51% | $561,573,459 |
| Capital World Investors | 1.8% | 9,517,337 | +18% | 0.06% | $533,637,086 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 8,058,048 | +2.4% | 0.02% | $450,581,226 |
| Caledonia (Private) Investments Pty Ltd | 1.1% | 5,775,851 | -19% | 11% | $323,851,966 |
| NORGES BANK | 0.98% | 5,336,084 | 0.03% | $299,194,230 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.89% | 4,826,617 | +6.5% | 0.01% | $270,628,415 |
| NORTHERN TRUST CORP | 0.87% | 4,718,859 | +24% | 0.03% | $264,586,425 |
| ROYAL LONDON ASSET MANAGEMENT LTD | 0.79% | 4,319,595 | +13% | 0.45% | $242,199,693 |
| AQR CAPITAL MANAGEMENT LLC | 0.79% | 4,305,412 | +14% | 0.08% | $241,404,423 |
| Invesco Ltd. | 0.78% | 4,232,577 | +13% | 0.02% | $237,320,598 |
| BANK OF AMERICA CORP /DE/ | 0.76% | 4,149,422 | +19% | 0.01% | $232,658,117 |
| Legal & General Group Plc | 0.7% | 3,800,504 | +13% | 0.04% | $213,094,266 |
| Amundi | 0.69% | 3,723,864 | +21% | 0.05% | $208,797,054 |
| VICTORY CAPITAL MANAGEMENT INC | 0.68% | 3,682,932 | -4.4% | 0.12% | $206,501,997 |
| Patient Capital Management, LLC | 0.66% | 3,598,808 | -1.2% | 6.7% | $201,785,166 |
| UBS Group AG | 0.58% | 3,143,347 | +73% | 0.03% | $176,247,466 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.57% | 3,083,528 | +1.8% | 0.02% | $172,893,415 |
| TWO SIGMA INVESTMENTS, LP | 0.54% | 2,920,163 | +30% | 0.12% | $163,733,539 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
Q2 2026
Rows shown
1-25 of 30
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 365,939,259 | $20,502,342,626 | +$692,560,746 | $56.07 | 638 |
| 2026 Q1 | 354,743,531 | $16,994,827,398 | -$5,573,344 | $47.97 | 589 |
| 2025 Q4 | 357,672,921 | $13,811,744,465 | +$1,025,655,761 | $38.64 | 538 |
| 2025 Q3 | 327,857,254 | $11,565,432,295 | -$513,196,140 | $35.28 | 484 |
| 2025 Q2 | 342,210,637 | $12,333,363,729 | +$949,776,240 | $36.03 | 452 |
| 2025 Q1 | 317,255,108 | $9,879,343,045 | -$34,196,805 | $31.13 | 444 |
| 2024 Q4 | 320,707,173 | $8,183,523,072 | +$144,649,409 | $25.51 | 414 |
| 2024 Q3 | 312,434,792 | $8,832,030,084 | -$70,655,781 | $28.29 | 391 |
| 2024 Q2 | 316,171,106 | $8,334,967,211 | +$126,311,822 | $26.37 | 373 |
| 2024 Q1 | 311,994,207 | $9,469,625,864 | +$68,283,642 | $30.37 | 375 |
| 2023 Q4 | 310,848,061 | $8,731,929,890 | +$90,598,401 | $28.09 | 359 |
| 2023 Q3 | 300,556,312 | $8,159,558,450 | -$95,718,367 | $27.14 | 312 |
| 2023 Q2 | 302,776,880 | $9,312,865,143 | +$35,406,560 | $30.74 | 321 |
| 2023 Q1 | 301,740,017 | $10,870,806,631 | +$87,185,612 | $36.03 | 331 |
| 2022 Q4 | 299,214,570 | $11,818,548,636 | +$83,591,490 | $39.52 | 332 |
| 2022 Q3 | 298,186,963 | $11,983,269,244 | +$263,400,168 | $40.18 | 311 |
| 2022 Q2 | 291,545,338 | $12,256,604,812 | +$918,924,477 | $42.04 | 281 |
| 2022 Q1 | 270,383,631 | $10,536,275,796 | +$82,755,109 | $38.96 | 272 |
| 2021 Q4 | 268,200,640 | $10,687,984,091 | +$139,946,049 | $39.85 | 254 |
| 2021 Q3 | 265,367,304 | $9,590,727,932 | +$538,289,516 | $36.14 | 226 |
| 2021 Q2 | 250,410,928 | $10,263,954,175 | +$118,347,007 | $40.99 | 229 |
| 2021 Q1 | 246,400,511 | $10,747,503,399 | +$874,104,377 | $43.62 | 208 |
| 2020 Q4 | 226,132,987 | $11,317,812,164 | +$1,961,711,795 | $50.05 | 188 |
| 2020 Q3 | 155,310,287 | $6,522,638,173 | +$367,540,942 | $42.07 | 129 |
| 2020 Q2 | 146,093,806 | $7,034,558,503 | +$7,034,558,867 | $48.55 | 119 |